$1.60
-0.26-13.98%
Last update: Nov 10, 1:42 PM
Black Diamond Therapeutics Inc
BDTXNASDAQ
Black Diamond Therapeutics fell 57.3% from $4.36 to $1.86, behind the S&P 500's +10.5%. Its worst day was May 22 (−35.8%), and its low came Jun 22 at $1.61.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Black Diamond Therapeutics closed at its highest level of the year, 11.7% above where the year started.
+5.4% · S&P 500 +0.1%
Black Diamond Therapeutics shares fell 29.6%, while the S&P 500 rose 0.1%.
Story events cover the past 12 months · Times ET
−29.6%, on 10M shares, the year's heaviest volume · S&P 500 +0.1%
Black Diamond Therapeutics shares fell 16.7%, while the S&P 500 fell 0.6%.
−16.7% · S&P 500 −0.6%
EPS of $-0.27 missed the $-0.17 estimate on $0.00 revenue.
+1.8% · S&P 500 +0.3%
EPS of $-0.16 beat the $-0.21 estimate on $0.00 revenue (est. $30.0M).
−3.5% · S&P 500 −0.3%
Preliminary mPFS of 15.2 months; mDOR not reachedRobust CNS activity, with 86% CNS ORR; no patients developed de novo brain metastasesORR 60% in patients with a broad spectrum of EGFR-NCMs, including PACCDose dependent
−35.8%, the year's worst day · S&P 500 +0.4%
Black Diamond Therapeutics closed at its lowest level of the year, 63.1% below where the year started.
−3.0% · S&P 500 −0.3%
EPS of $-0.17 beat the $-0.20 estimate on $0.00 revenue (est. $30.0M).
+7.3% · S&P 500 −0.2%
Black Diamond Therapeutics shares rose 14.4%, while the S&P 500 rose 0.3%.
+14.4% · S&P 500 +0.3%
Where it ended: a close of $1.86 on Nov 9, 2026. Up next: Q3 2026 earnings on Nov 24, 2026 (EPS est. $-0.05, revenue est. $15.0M).
Nothing in the past 12 months.
All BDTX dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for BDTX and SPY from Benzinga historical bars. Not investment advice.
